

Schaffhausen, January 7, 2015

**Announcement according to Art. 9 and Art. 21 SESTO-FINMA
Disclosure of shareholdings**

Pursuant to Art. 9 and Art. 21 SESTO-FINMA, Paul E. Singer, New York, USA, has announced to BB Biotech AG, Schaffhausen, Switzerland on December 30, 2014, that its holding in registered shares BB Biotech AG (ISIN CH0038389992) increased to more than 5% of the proportion of voting rights on December 19, 2014.

Paul E. Singer, New York, USA, held 648 547 voting rights (5.47% of the proportion of voting rights) as per December 19, 2014, indirectly by the companies listed below:

Direct Holders:

- Cornwall (Luxembourg) S.à.r.l., Luxembourg

Indirect Holders:

- Wolverton (Luxembourg) S.à.r.l., Luxembourg
- Maidenhead LLC, New York, USA
- Warrington LLC, New York, USA
- Elliott Associates, L.P., New York, USA
- Elliott Capital Advisors, L.P., New York, USA
- Elliott Special GP, LLC, New York, USA
- Braxton Associates, Inc., New York, USA
- Elliott Asset Management LLC, New York, USA
- Elliott International Limited, Grand Cayman, Cayman Islands
- Elliott International Capital Advisors Inc., New York, USA

For further information, please contact:

Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland
Tanja Chicherio, Tel. +41 44 267 67 07, tch@bellevue.ch
www.bbbiotech.com

Company profile

BB Biotech invests in companies in the fast growing market of biotechnology and is one of the world's largest investors in this sector with CHF 2.8 billion in assets under management. BB Biotech is listed in Switzerland, Germany and Italy. Its investments are focused on listed companies that are developing and commercializing novel medical treatments and cures. BB Biotech's investment selection process is guided by the fundamental research and analysis of physicians and molecular biologists. Its Board of Directors has many years of experience in industry and science.